Aims: To investigate whether the use of SGLT-2 inhibitors is associated with an increased risk of fractures.
| INTRODUCTION
Sodium-glucose co-transporter type 2 (SGLT-2) inhibitors are a novel drug class for the management of type 2 diabetes. 1 SGLT-2 inhibitors lead to improved glycaemic control by inhibiting the reabsorption of filtered glucose in the proximal renal tubules, thereby increasing the excretion of glucose in the urine. The resulting osmotic diuresis produced by SGLT-2 inhibitors with concomitant sodium loss leads to volume depletion and a reduction of arterial blood pressure. 1 Consequently, SGLT-2 inhibitors are not recommended in patients receiving loop diuretics, in volume depleted patients, or in those older than 75 years because of possible adverse effects. [2] [3] [4] In the United States, canagliflozin was approved as the first substance of this class in 2013, followed by dapagliflozin and empagliflozin in 2014. In September 2015, the US Food and Drug
Administration issued a warning concerning a possibly increased risk of fractures with the use of canagliflozin, 5 which was based on a pooled analysis of nine randomized controlled trials (RCTs) that showed a statistically significant increase in the incidence of adjudicated fractures, primarily in the upper and lower limbs, among users of canagliflozin (2.7%) vs those who did not use canagliflozin (1.9%). 6 This result was triggered mainly by the interim analysis of the CANagliflozin cardiovascular Assessment Study (CANVAS), which revealed an elevated incidence of fracture with canagliflozin (4.0%) vs placebo (2.6%). 6 In a phase 3 placebo-controlled RCT, there was further evidence of a statistically significant reduction in hip bone mineral density in older patients after 2 years of treatment with canagliflozin. 7 In contrast, no increased risk of fractures was found with canagliflozin in the pooled group of studies outside the CANVAS study 6 or with SGLT-2 inhibitors as drug class in four meta-analyses pooling data from primarily placebo-controlled RCTs. 1, 8 In addition, no increased risk of treatment-emergent fractures was observed with dapagliflozin compared to standard antidiabetic treatment in an observational study from the United Kingdom. 12 Given the conflicting evidence and the lack of actively controlled studies based on real-world data to support treatment decisions in clinical practice, we investigated whether the use of SGLT-2 inhibitors is associated with an increased risk of fractures compared to use of other second-or third-line treatments in patients with type 2 diabetes.
| MATERIAL AND METHODS

| Data source
This study was based on data from the InGef (former HRI) database. At the time of analysis, the database included anonymized longitudinal claims data from approximately 6.7 million Germans insured by one of 64 German statutory health insurances (SHIs) contributing to the database. In brief, the InGef database includes the following information:
demographic data (eg, age, sex and region of residence); data concerning ambulatory services and diagnoses; hospital data, including admission and discharge dates, the main and secondary discharge diagnoses and procedures conducted in hospital; drug prescription and dispensing data, with the date of prescription and drug dispensation; data concerning reimbursed remedies and aids; and the costs of each healthcare sector of the German SHIs. All diagnoses in the database are coded according to the German modification of the 10th revision of the International Classification of Diseases (ICD-10 GM). 13 All patient-level data in the InGef database are de-identified to comply with German data protection regulations and German federal law. Hence, approval of an institutional review board or Ethics Committee was not required.
| Study population
We conducted a cohort study with a nested case-control analysis in new users of non-insulin antidiabetic drugs between the approval date of dapagliflozin as the first SGLT-2 inhibitor in Germany on November (Table S2 in Appendix S2). We focused on fractures of the upper and lower limbs, as these were mainly responsible for triggering the increased risk in the CANVAS trial. 6 The index date of the case was defined as the admission date of hospitalization or the date of the claim for the diagnostic procedure indicating a fracture of the upper or lower limbs in the outpatient setting. For each case, up to 40 control subjects were randomly sampled from the individual risk set, that is, among all other patients in the cohort who were event free and were still being followed at the index date of the case. Control subjects were matched according to age, sex, date of cohort entry (+/−180 days) and duration of follow up. The index date of the control was the same as that of the respective case.
| Exposure assessment
For all cases and their matched control subjects, current use of noninsulin antidiabetic drugs was assessed at the index date, as well as current use of insulin, as metformin plus insulin is a recommended second-line treatment according to guidelines of the German Diabetes Society. 14 tor was used as the reference, as they are most commonly used as second-line therapy for type 2 diabetes in Germany. 15 
| Statistical analysis
The crude incidence rate of fractures in the overall cohort was calculated with corresponding 95% confidence intervals (CIs), assuming a
Poisson distribution. Conditional logistic regression was used to estimate odds ratios (ORs) with 95% CIs of fractures, comparing current use of metformin plus SGLT-2 inhibitor or metformin plus another antidiabetic drug class to metformin plus a DPP-4 inhibitor as reference. In the first step, bivariate analyses were conducted for each potential confounder and the risk of fractures, including indicators for type 2 diabetes severity and complications, co-morbidities of type 2 diabetes, and risk factors for fractures and falls (Tables S3-S5 in Appendix S1.). The final multivariate model included all variables that were statistically significant in these analyses. In addition, disorders of bone density and structure, cancer and the adapted Diabetes Complication Severity Index 16 were included as pre-defined covariates. As risk-set sampling was performed in the matching process, the odds ratios can be interpreted as unbiased estimators of the hazard ratio.
17,18
We conducted six pre-specified subgroup analyses. First, we performed a stratified analysis for patients with and without a history of All statistical analyses were conducted with SAS, version 9.4 (SAS Institute, Cary, North Carolina).
| RESULTS
The study cohort comprised a total of 210 042 new users of noninsulin antidiabetic drugs (Figure 1 ) with a mean age of 63.9 years (standard deviation, 12.8 years), of whom 57.6% were male. During follow-up, we observed 7523 cases with fractures of the upper or lower limbs, corresponding to an incidence rate of 13.8 per 1000
person-years (95% CI, 13.5-14.1). The majority of patients entered the cohort with a prescription for metformin (47.1%), followed by sitagliptin (13.5%) and the fixed combination of metformin plus sitagliptin (11.1%) ( Table S6 in Appendix S1). Table 1 ). The characteristics of cases and control subjects are displayed in Table 2 and Table S7 in Appendix S1. Overall, cases had a higher prevalence of most indicators of type 2 diabetes severity and of type 2 diabetes-related complications and co-morbidities, and they were more frequently affected by risk factors for falls and fractures compared to control subjects. (Table 3) . Similarly, no statistically significant association was found for current use of metformin in combination with any other drug class in the crude and confounder adjusted analyses (Table 3) (Table S8 in Appendix S1).
| DISCUSSION
In this study based on real-world data, current use of metformin plus an SGLT-2 inhibitor was not associated with an elevated risk of fractures of the upper or lower limbs when compared to current use of FIGURE 2 Association between current use of metformin plus an SGLT-2 inhibitor vs metformin plus a DPP-4 inhibitor and fractures of the upper or lower limbs in pre-defined subgroups. a Multivariate analysis was adjusted for the following variables: disorders of bone density and structure, including osteoporosis; status according to the adapted Diabetes Complication Severity Index (classified <2 vs 2+): type 2 diabetes with renal complication, eye complication, neurological complication and peripheral vascular complication: ischaemic stroke; other cerebrovascular disease; ischaemic heart disease; other vascular disease; chronic renal disease; history of insulin use; Cushing syndrome; hyperparathyroidism; hyperthyroidism; post-gastric surgery syndrome; testicular hypofunction in men; inflammatory polyarthropathies; inflammatory bowel disease; androgen deprivation; use of corticosteroids, proton-pump inhibitors, drugs affecting bone metabolism and density, including bisphosphonates and denosumab, calcitonin; diabetic coma; hypoglycaemia; heart failure; cardiac arrhythmias and conduction disorders; epilepsy; fluid and electrolyte disorders; nursing home residence; Parkinson's disease; other movement disorders; dementia; alcohol or substance abuse; vertigo and dizziness; use of loop diuretics, other diuretics, beta blockers, antiepileptic drugs, opioids, sedatives or hypnotics, anxiolytics, antidepressants, antipsychotics, muscle relaxants; status according to the Charlson Comorbidity Index (classified <2 vs 2+), hospitalization (yes vs no), number of ambulatory physician contacts (classified <11 vs 11+) and number of different drugs used (classified <8 vs 8+) metformin plus DPP-4 inhibitor. In addition, no dose-response relationship was observed for current dose or cumulative dose of SGLT-2 inhibitors and no increased risk was found for individual SGLT-2 inhibitor substances and for subgroups at risk for falls and fractures, that is, patients aged 75 years or more and those with four or more risk factors for falls and fractures.
In general, two possible mechanisms have been discussed for the increased risk of fracture with SGLT-2 inhibitors. First, SGLT-2 inhibitors may increase the risk of fall-related fractures through symptoms of volume depletion such as postural dizziness or orthostatic hypotension. 20 Second, a decline in bone mineral density, caused by SGLT-2 inhibitors, might lead to increased risk of fracture. 21 So far, evidence regarding increased risk of fracture with use of SGLT-2 inhibitors is conflicting. The increased risk of fractures which had been observed in the interim analysis of the CANVAS study 6 was confirmed in the final analysis, with a hazard ratio of 1.55 (95% CI, 1.21-1.97) for all fractures and a hazard ratio of 1.56 (95% CI, 1.18-2.06) for low trauma fractures. In contrast, no excess risk was observed in the CANVASRenal study, a sister trial with nearly identical inclusion criteria. 22 Likewise, no increased risk of fracture was found in four meta-analyses that pooled data from primarily placebo-controlled RCTs for dapagliflozin, canagliflozin and empagliflozin [8] [9] [10] [11] and in the pooled non-CANVAS studies. 6 In a matched cohort study from the United other antidiabetic treatments. [25] [26] [27] [28] Similarly, we could not find in our study a statistically significant difference between all antidiabetic drug classes, compared to DPP-4 inhibitors.
A major strength of this study was the opportunity to assemble a large cohort of patients with T2DM who initiated treatment with non- 16 We did not find meaningful differences with regard to the effect estimates for SGLT-2 inhibitors in the crude and confounder-adjusted analysis, which argues against a strong impact of residual and unmeasured confounding. As fracture case adjudication based on external medical records was not possible in this study, we 
